Sanginita Chemicals Ltd. (SANGINITA) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): N/A
• Revenue Growth: 0.45%
• EPS Growth: -242.94%
• Country: IN
• Employees: 60
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals
• EPS (TTM): -0.26
• Shares Outstanding: N/A
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: -0.92
• Price to Book (P/B): 0.52
• Price to Sales (P/S): 0.13
• P/FCF Ratio: -3.49
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: ―

The overall stock score for Sanginita Chemicals is primarily influenced by financial performance, which indicates significant pressure on profitability and cash generation. The absence of technical analysis and valuation data limits the evaluation, resulting in lower scores for those components.

Sanginita Chemicals Ltd. Business Overview & Revenue Model

Company Description

Sanginita Chemicals Ltd. (SANGINITA) is a leading manufacturer and supplier in the specialty chemicals sector, focusing primarily on the production of high-quality chemical intermediates and specialty products for various industries, including pharmaceuticals, agrochemicals, and personal care. With a commitment to innovation and sustainability, the company leverages advanced technology and a skilled workforce to deliver tailored solutions that meet the diverse needs of its global clientele.

How the Company Makes Money

Sanginita Chemicals Ltd. generates revenue through multiple streams primarily centered around the production and sale of specialty chemicals. The company earns money by manufacturing chemical intermediates that are essential for various end products in sectors such as pharmaceuticals, agrochemicals, and personal care. Additionally, SANGINITA engages in long-term contracts with key clients, ensuring a steady flow of income. The company also benefits from strategic partnerships with other manufacturers and suppliers, which enhance its market reach and operational capabilities. SANGINITA's revenue model is further bolstered by its investment in research and development, allowing it to innovate and expand its product offerings, leading to increased sales and market share.

Sanginita Chemicals Ltd. Financial Statement Overview

Summary

Sanginita Chemicals presents a mixed financial performance. The income statement shows pressure on profitability with fluctuating revenue growth and declining net profit margins. The balance sheet is stable but with low return on equity, and the cash flow statement highlights significant challenges in cash generation due to negative free cash flow, pointing to the need for improved cash management.

Income Statement

Sanginita Chemicals displays mixed performance in its income statement. The gross profit margin has been under pressure, and there's a declining trend in net profit margin, reflecting challenges in cost management or pricing power. Revenue growth has been inconsistent, with fluctuations in EBIT and EBITDA margins indicating operational inefficiencies. Overall, the company shows a moderate performance with room for improvement in profitability.

Balance Sheet

The balance sheet shows a reasonable degree of stability, with a manageable debt-to-equity ratio indicating moderate leverage. The equity ratio suggests a balanced capital structure. However, the return on equity is relatively low, which may point to inefficiencies in utilizing shareholder capital. The company maintains a stable asset base, but optimizing returns remains a focus area.

Cash Flow

Cash flow analysis reveals challenges, particularly with negative free cash flow over recent periods. The operating cash flow to net income ratio indicates some conversion efficiency issues. While the company has managed to secure financing, the lack of consistent free cash flow growth is a concern, highlighting the need for better cash management and operational cash generation.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.19B	2.30B	1.52B	1.49B	1.98B	1.65B
Gross Profit	61.30M	52.91M	49.17M	72.70M	61.60M	71.11M
EBITDA	47.91M	49.43M	44.09M	36.05M	31.10M	41.93M
Net Income	4.12M	6.18M	7.70M	4.16M	3.48M	7.63M
Balance Sheet
Total Assets	0.00	1.02B	859.29M	794.99M	792.04M	701.22M
Cash, Cash Equivalents and Short-Term Investments	129.00K	129.00K	205.00K	272.00K	149.00K	84.00K
Total Debt	0.00	263.76M	328.66M	285.80M	345.14M	289.51M
Total Liabilities	-561.45M	461.57M	451.35M	393.62M	394.83M	307.49M
Stockholders Equity	561.45M	561.45M	407.94M	401.37M	397.21M	393.73M
Cash Flow
Free Cash Flow	0.00	-83.50M	-62.01M	128.14M	-36.34M	82.32M
Operating Cash Flow	0.00	8.42M	-22.96M	137.01M	-29.88M	85.11M
Investing Cash Flow	0.00	-99.00M	-38.70M	-7.29M	-4.96M	-1.37M
Financing Cash Flow	0.00	90.51M	61.60M	-129.59M	34.90M	-83.93M

Sanginita Chemicals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BHAGERIA	72 Outperform	₹9.33B	18.31	―	0.72%	33.39%	85.08%
CHEMBOND	70 Outperform	₹2.24B	9.77	―	1.05%	-37.34%	-45.55%
20MICRONS	62 Neutral	₹7.62B	12.42	―	0.61%	7.23%	5.00%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
SADHNANIQ	54 Neutral	₹2.43B	49.50	―	1.43%	-15.63%	3.19%
SANGINITA	46 Neutral	―	―	―	―	0.45%	-242.94%

Sanginita Chemicals Ltd. Corporate Events

Sanginita Chemicals Ltd. Conducts 20th AGM Virtually, Highlights Financial Performance and Rights Issue

Sanginita Chemicals Ltd. held its 20th Annual General Meeting on August 2, 2025, conducted virtually in compliance with regulatory provisions. The meeting included an overview of the company’s financial and operational performance for the fiscal year ending March 31, 2025, and discussed a Rights Issue made during the year. Members were given the opportunity to vote electronically and engage with the management on financial statements and related queries.